Advocacy groups recently used social media to sway the biopharma industry. And not only did the effort – which involved a high-profile influencer – alter a decade-long battle over access to tuberculosis products, but it may embolden other advocates to use social media to best companies at their own game.
The John Green Effect: Will Industry Be Influenced Again?
The Fault In Our Global Access To Medicines Practices
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.

More from Business Strategy
More from In Vivo
• By
In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
CMO Tahamtan Ahmadi explained Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.